scispace - formally typeset
J

Jung Won Choi

Researcher at Seoul National University

Publications -  14
Citations -  279

Jung Won Choi is an academic researcher from Seoul National University. The author has contributed to research in topics: Brain tumor & Peroxidase. The author has an hindex of 9, co-authored 14 publications receiving 218 citations. Previous affiliations of Jung Won Choi include New Generation University College & Seoul National University Hospital.

Papers
More filters
Journal ArticleDOI

Stricter indications are recommended for fenestration surgery in intracranial arachnoid cysts of children.

TL;DR: It was showed that the fenestration procedure for AC produced unsatisfactory clinical improvements compared to the relatively high complication rate, and surgical treatment for AC should be strictly limited to patients who have symptoms directly related to AC.
Journal ArticleDOI

Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.

TL;DR: The therapeutic potential of DSF against BTICs from AT/RT is demonstrated and the possibility of ALDH inhibition for clinical application is suggested.
Journal ArticleDOI

Posterior cerebral artery involvement in moyamoya disease: initial infarction and angle between PCA and basilar artery

TL;DR: Involvement of PCA in MMD may occur in a delayed fashion, years after the completion of revascularization of anterior circulation, and persistent long-term follow-up regarding the posterior circulation is recommended.
Journal ArticleDOI

Clinical outcome of pediatric choroid plexus tumors: retrospective analysis from a single institute

TL;DR: CPP and ACPP were surgically curable and multi-modal treatments are necessary in the management of CPC with poor prognosis, and HDCT and aPBSCT may be important to treat infants for whom radiotherapy is limited.
Journal ArticleDOI

Human Adipose Tissue-Derived Mesenchymal Stem Cells Target Brain Tumor-Initiating Cells

TL;DR: Both in vitro and in vivo experiments showed that hAT-MSCs possess migratory abilities to target BTICs isolated from medulloblastomas, atypical teratoid/rhabdoid tumors (AT/RT) and glioblastoma, implying the potential use of MSCs as a delivery vehicle for gene therapy.